FILTER

Refine your search with the following facets to narrow down your results.

4 Current news of Idenix Pharmaceuticals

Idenix Pharmaceuticals Initiates Proof-of-Concept Study for Protease Inhibitor IDX320 in Hepatitis C Patients

14-Jun-2010 - Idenix Pharmaceuticals, Inc. announced that it has initiated a 3-day proof-of-concept study of IDX320, a protease inhibitor for the treatment of hepatitis C virus (HCV) infection, under a Clinical Trial Application (CTA). The study is evaluating IDX320 in treatment-naive hepatitis C genotype ...

clinical trials hepatitis C inhibitors +1

Idenix Pharmaceuticals Presents Data on IDX184 for the Treatment of Hepatitis C Virus (HCV)

03-Nov-2009 - Idenix Pharmaceuticals, Inc. announced presentations of data on IDX184, a once-daily novel liver-targeted nucleotide prodrug of 2'-methyl guanosine (2'MeG) for the treatment of HCV, at the annual meeting of the American Association for the Study of Liver Diseases (AASLD) currently being held in ...

diarrhea dosing Formation +6

Galapagos enters into discovery collaboration with Idenix for infectious disease programs

25-Nov-2005 - Galapagos NV announced that it has entered into a collaboration with Idenix Pharmaceuticals, Inc. on selected hepatitis and HIV infectious disease programs. Pursuant to the collaboration, Galapagos' service division BioFocus will supply its proprietary SoftFocus® chemical compound collections to ...

Galapagos infectious diseases medicinal chemistry +1

Novirio Pharmaceuticals Limited Becomes Idenix Pharmaceuticals , Inc.

31-May-2002 - CAMBRIDGE, Mass., May 29, 2002 - Novirio Pharmaceuticals Limited, a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral and other infectious diseases, today announced that the company has changed its name to Idenix Pharmaceuticals, Inc. The ...

hepatitis C infectious diseases